On August 25, 2026, the U.S. Food and Drug Administration (FDA) announced the selection of initial participants to advance to the interaction phase of the READI-Home Challenge, a program launched by the Center for Devices and Radiological Health (CDRH) to encourage the development of medical devices that can be used at home after an acute hospital stay, with the goal of helping reduce avoidable readmissions.
Selection of any technology to participate in the challenge does not constitute FDA marketing authorization, nor does it guarantee the outcome of any future regulatory submission. The agency says it continues to review applications and intends to update the participant list whenever additional entities are selected.
What Does the Challenge Include?
READI-Home consists of two phases. The application period for the selection phase began on April 7, 2026, and continues through September 30, 2026, while the FDA intends to notify all selected participants no later than December 4, 2026. The agency may select participants before applications close.
Those selected advance directly to the interaction phase after notification, during which they receive early and intensive communication with FDA staff through short, recurring discussions known as “sprint” discussions. These discussions are intended to refine the device design or testing plans associated with its use at home, while providing an opportunity to demonstrate the technology at the agency’s research facilities.
The FDA expects to select up to nine devices from different manufacturers. No more than one device from the same manufacturer may advance to the interaction phase, even if the company submits information on multiple devices.
First Technologies Selected
The initial list includes two devices:
- Epitel, Inc. – REMI Neuro Monitoring Home Health Hub: A wireless wearable electroencephalography (EEG) system intended for extended monitoring after hospital discharge and in home and mobile environments. It targets people aged six years and older who are being evaluated for seizures, sleep impairment, or delirium, either after a hospital stay or as a potential alternative to admission.
- Prapela, Inc. – Prapela Therapeutic Vibrational Crib Mattress: An infant crib mattress equipped with a miniaturized vibration actuator that delivers low-amplitude, broadband mechanical vibration during infant sleep. It is proposed for reducing the frequency, duration, and severity of hypoxic and bradycardic episodes in infants with single-ventricle heart disease during the interstage period, which lasts approximately three to six months.
Why Does This Matter?
The FDA links the initiative to a broad clinical and economic problem: 30-day readmission rates among people with chronic diseases range from 2.8% to 18.4%, while the rate among patients without chronic diseases was 13.9% between 2016 and 2020. The agency notes that more than half of readmissions among people with chronic diseases occur for reasons different from the initial admission, and that the cost of a readmission is approximately 12% higher than the cost of the original stay.
In practical terms, the initiative gives companies a structured pathway for obtaining early interaction with the regulator before later stages of development. Devices described in a Q-Submission information request may be considered for the Breakthrough Device designation or the Safer Technologies Program, depending on their suitability. However, this possibility is not a guaranteed outcome.
Eligibility Requirements and Limitations
The innovation should fall within the definition of a “device” under the U.S. Federal Food, Drug, and Cosmetic Act and address an unmet or emerging health need in the home, with a patient or caregiver among the intended users and a home or community setting included in the use environment. The FDA also requests evidence supporting the likelihood of reducing readmissions and the feasibility of implementing the device, along with information about its design, the novelty of the technology, its development status, the data development plan, the team’s experience, and the expected impact.
An English-language PDF of no more than 16 pages, excluding references, must be submitted through the CDRH portal before September 30, 2026. The generalizability of the results and the demonstration of the devices’ effectiveness in reducing readmissions remain open questions that will depend on subsequent testing and data, not on participation in the challenge alone.